The 1.6mm laser fiber probe features patented NeuroBlate System cooling technology and is available in a single adjustable length.
Minnetonka, Minnesota-based Monteris won FDA 510(k) clearance to add the NB3 to its NeuroBlate system’s devices and accessories in December 2023 and started a limited market release in February.
“Surgeons participating in the initial launch phase used the probe across a comprehensive set of workflows, lesion types, sizes, locations, target depths and patient profiles,” the company said in a news release. “Lesion types include primary tumors, progressive metastatic lesions, radiation necrosis and epileptogenic foci in both adult and pediatric patients. Lesion sizes ablated during limited market release have ranged from less than 10mm in diameter to nearly 30mm in diameter and have included deep-seated targets and multiple trajectory procedures.”
Monteris designed the NB3 laser probe for power settings ranging from 6 W to 12 W for delivery of small to large ablations.
“We are thrilled to bring the highly anticipated NB3 laser probe to our neurosurgeons and hospital system customers for use across a broad spectrum of patient needs, including the pediatric [laser interstitial thermal therapy] population,” Monteris President and CEO Martin Emerson said in the news release. “NB3, used in combination with Monteris’ best-in-class NeuroBlate software and robotics, provides our neurosurgeon users the precision and flexibility they demand for their patients. We expect the forward-thinking engineering incorporated into NB3 will become the platform for our future probe designs. In addition, our near-term cadence of new software releases will put even greater options in the hands of our neurosurgeon customers.”
